Books, Posters, Presentations from 2020
Assessing Time from Door-to-Antibiotic Administration for Adult Cancer Patients with Neutropenic Fever in the Emergency Department, Sarah Roy and Tina Magsarili
Assessing Time from Door-to-Antibiotic Administration for Adult Cancer Patients with Neutropenic Fever in the Emergency Department, Sarah Roy and Tina Magsarili
Part Two: 24. Skin Cancer, Krista M. Rubin Ed. and Christine Boley Ed.
Facebook Live: Lung Cancer awareness and da Vinci robotic surgery, Cheri Russum, Kimberly E Costas, and Luis F Alberton
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges., Sergio Rutella, Michael A Cannarile, Sacha Gnjatic, Bruno Gomes, Justin Guinney, Vaios Karanikas, Mohan Karkada, John M Kirkwood, Beatrix Kotlan, Giuseppe V Masucci, Els Meeusen, Anne Monette, Aung Naing, Vésteinn Thorsson, Nicholas Tschernia, Ena Wang, Daniel K Wells, Timothy L Wyant, and Alessandra Cesano
Parathyroidectomy and Hypertension-Reply., Meena Said
Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling., Ravi Salgia, Isa Mambetsariev, Tingting Tan, Amanda Schwer, Daryl Pearlstein, Hazem Chehabi, Angel Baroz, Jeremy Fricke, Rebecca Pharaon, Hannah Romo, Thomas Waddington, Razmig Babikian, Linda Buck, Prakash Kulkarni, Mary Cianfrocca, Benjamin Djulbegovic, and Sumanta K Pal
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3), Rachel E Sanborn, Ralph Hauke, Nashat Gabrail, Mark O'Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Diego Alavardo, Laura Vitale, Tibor Keler, and Michael Yellin
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3), Rachel E Sanborn, Ralph Hauke, Nashat Gabrail, Mark O'Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Mark Rogalski, Diego Alvarado, Laura Vitale, Tibor Keler, and Michael Yellin
Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC)., Katherine Sanchez, Shu-Ching Chang, Isaac Kim, Maritza Martel, Yaping Wu, William L. Redmond, Zhaoyu Sun, Dottie Waddell, Deborah R. Laxague, Brady Bernard, Monil Shah, Walter Urba, and David B. Page
Part One: 11. Clinical Trials and Research Protocols, Marlon G Saria Ed. and Santosh Kesari Ed.
Part Two: 9. Precision Medicine, Marlon G Saria Ed. and Santosh Kesari Ed.
Complementary and Alternative Medicine Attitudes and Use in Caregivers of Patients with Lung Cancer, Trisha Saul, Lorraine Evangelista, Jung-Ah Lee, Sangyhuk Shin, and Michelle Fortier
Inaccurate pretreatment staging can impact survival in early stage esophageal adenocarcinoma., Anthony J Scholer, Abhineet Uppal, Shu-Ching Chang, Debopriya Ghosh, Mary Garland-Kledzik, Juan A Santamaria-Barria, Adam Khader, Ahmed Dehal, Trevan D Fischer, and Melanie Goldfarb
Clinical application of next generation sequencing in lymphoma., Anthony J Scott, Molly C Tokaz, Maryann M Shango, Sumana Devata, Shannon A Carty, Mark S Kaminski, Arul M Chinnaiyan, Tycel J Phillips, and Ryan A Wilcox
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study., Alison R. Sehgal, Gerhard Hildebrandt, Nilanjan Ghosh, John E Godwin, Nina D. Wagner-Johnston, Daanish Hoda, Edward J. Licitra, Javier Munoz, Nikolaus S. Trede, Lei Wang, Jerill Thorpe, and Leo I. Gordon
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC., Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schroder, Kevin M. Chin, Joseph Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, and Maurice Zauderer
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies., Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schroder, Kevin M. Chin, J Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yan Yan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, and Maurice Zauderer
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies., Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schroder, Kevin M. Chin, J Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, and Maurice Zauderer
A Pilot Study to Assess the Integration of a Unique PROQOL Tool and Early Palliative Care Intervention in the Care of High Grade Glioma Patients and their Caregivers (2633), Akanksha Sharma and See full list of authors in comments
Longitudinal Perception of Prognosis of Patients with High Grade Glioma Compared to their Caregivers and Clinicians (2588), Akanksha Sharma and See full list of authors in comments
1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours, M Sharma, Rachel E Sanborn, GM Cote, JC Bendell, S Kaul, F Chen, A Berezhnoy, P Moore, E Bonvini, BJ Sumrow, and JJ Luke
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial., Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A Woyach, Gilles Salles, William G Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, and John C Byrd
Use of a report card to evaluate outcomes of achalasia surgery: beyond the Eckardt score., Ealaf Shemmeri, Ralph W Aye, Alexander S Farivar, Adam J Bograd, and Brian E Louie
Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC., Takehito Shukuya, Vikas Ghai, Joseph M Amann, Tamio Okimoto, Konstantin Shilo, Taek-Kyun Kim, Kai Wang, and David P Carbone
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors, Elaine Shum, Adil Daud, Matthew Reilley, Yana Najjar, John Thompson, Joaquina Baranda, R Donald Harvey, Rom Leidner, Anthony Shields, Ezra Cohen, Roger Cohen, Alain Mita, Shubham Pant, Mark Stein, Bartosz Chmielowski, Siwen Hu-Lieskovan, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Raphael Clynes, and Barbara Hickingbottom
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors, Elaine Shum, Adil Daud, Matthew Reilley, Yana Najjar, John Thompson, Joaquina Baranda, R Donald Harvey, Rom Leidner, Anthony Shields, Ezra Cohen, Alain Mita, Shubham Pant, Mark Stein, Bartosz Chmielowski, Siwen Hu-Lieskovan, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Raphael Clynes, and Barbara Hickingbottom
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment., David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag, Jesus Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S Seet, Giampaolo Talamo, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, William E Pierceall, Weiyuan Chung, Faiza Zafar, Amit Agarwal, and Nizar J Bahlis
Review of Procedures and Outcomes of Video-Assisted Thoracic Surgery for the Treatment of Non-Small Cell Lung Cancer in 45 Patients Undergoing Segmentectomy., Rachel Sier and Osita Onugha
Elevating your breast program to the next level., Melvin J Silverstein
Empowering Clinical Nurses: Decreasing Clostridium Difficile, Danielle N. Sloane and Michelle McSherry
Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes., Alicia Smart, Daniela Buscariollo, Gabriela Alban, Ivan Buzurovic, Teresa Cheng, Jennifer Pretz, Betty Krechmer, Martin King, and Larissa Lee
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia., Catherine C Smith, Mark J Levis, Olga Frankfurt, John M Pagel, Gail J Roboz, Richard M Stone, Eunice S Wang, Paul L Severson, Brian L West, Mai H Le, Sabine Kayser, Bao Lam, Henry H Hsu, Chao Zhang, Gideon Bollag, and Alexander E Perl
The Cancer Rehabilitation Medicine Metrics Consortium: A Path to Enhanced, Multi-Site Outcome Assessment to Enhance Care and Demonstrate Value., Sean R Smith, Mary Vargo, David S Zucker, Maryanne Henderson, Samman Shahpar, Eric M Wisotzky, Christian Custodio, Jeffrey Basford, Gina Jay, Lynn Gerber, and Andrea Cheville
Surgical Management of Non-Small Cell Lung Cancer Invading the Fissure: Less Is More?, Shane P Smith, Adam J Bograd, Gal Levy, Shu-Ching Chang, Alexander S Farivar, Ralph W Aye, Brian Louie, and Eric Vallieres
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial., David R Spigel, Robert M Jotte, Santiago Ponce Aix, Laurent Gressot, Daniel Morgensztern, Michael McCleod, Mark A Socinski, Davey Daniel, Oscar Juan-Vidal, Kathryn F Mileham, Howard J. West, Ray Page, Niels Reinmuth, Jeanna Knoble, Tianlei Chen, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Cesare Gridelli, and Michael Thomas
What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?, Hayley Standage, Alyssa R Hersh, Aaron Caughey, Matthew H Taylor, John Vetto, and Dale Han
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration., Deborah M Stephens, Ken Boucher, Elizabeth Kander, Sameer A Parikh, Erin M Parry, Mazyar Shadman, John M Pagel, Jennifer Cooperrider, Joanna Rhodes, Anthony Mato, Allison Winter, Brian Hill, Sameh Gaballa, Alexey Danilov, Tycel Phillips, Danielle M Brander, Sonali M Smith, Matthew Davids, Kerry Rogers, Martha J Glenn, and John C Byrd
An exercise oncology clinical pathway: Screening and referral for personalized interventions., Nicole L Stout, Justin C Brown, Anna L Schwartz, Timothy F Marshall, Anna M Campbell, Larissa Nekhlyudov, David S Zucker, Karen M Basen-Engquist, Grace Campbell, Jeffrey Meyerhardt, Andrea L Cheville, Kelley R Covington, Jennifer A Ligibel, Jonas M Sokolof, Kathryn H Schmitz, and Catherine M Alfano
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade (ICB) is associated with induction of pro-inflammatory Tregs, Elizabeth Sturgill, Courtney Mick, Johanna K. Kaufmann, and William L. Redmond
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors., Vivek Subbiah, Mini I-Nan Hu, Justin F. Gainor, Aaron Scott Mansfield, Guzman Alonso, Matthew H Taylor, Viola Weijia Zhu, Pilar Garrido Lopez, Alessio Amatu, Robert C. Doebele, Philippe Alexandre Cassier, Bhumsuk Keam, Martin H. Schuler, Hui Zhang, Corinne Clifford, Michael Palmer, Jennifer Green, Christopher D. Turner, and Giuseppe Curigliano
Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer., Ryan Sun, Miao Xu, Xihao Li, Sheila Gaynor, Hufeng Zhou, Zilin Li, Yohan Bossé, Stephen Lam, Ming-Sound Tsao, Adonina Tardon, Chu Chen, Jennifer Doherty, Gary E Goodman, Stig E Bojesen, Maria T Landi, Mattias Johansson, John K Field, Heike Bickeböller, H-Erich Wichmann, Angela Risch, Gadi Rennert, Suzanne Arnold, Xifeng Wu, Olle Melander, Hans Brunnström, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Eric Duell, Lambertus A Kiemeney, Hongbing Shen, Aage Haugen, Mikael Johansson, Kjell Grankvist, Neil Caporaso, Penella Woll, M Dawn Teare, Ghislaine Scelo, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B Schabath, Melinda C Aldrich, Demetrios Albanes, Raymond Mak, David Barbie, Paul Brennan, Rayjean J Hung, Christopher I Amos, David C Christiani, and Xihong Lin
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device., Vinitha Sree S, Rob Royea, Kevin J Buckman, Matt Benardis, Jim Holmes, Ronald L Fletcher, Ng Eyk, U Rajendra Acharya, and Joshua D I Ellenhorn
Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma., Sriman Swarup, Jonathan Kopel, Kyaw Zin Thein, Kaiser Tarafdar, Khatrina Swarup, Seshadri Thirumala, and Donald P Quick
Spontaneous heparin induced thrombocytopenia (HIT) following curettage and bone graft of femur in a patient with monostotic fibrous dysplasia., Sriman Swarup, Jonathan Kopel, Rachana Yendala, Seshadri Thirumala, and Donald Quick
560 Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo, Fernanda Szewc, Longzhen Song, Sean Rinella, Christopher Dubay, Emmanuel Akporiaye, William L. Redmond, and Christian Capitini
560 Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo, Fernanda Szewc, Longzhen Song, Sean Rinella, Christopher Dubay, Emmanuel Akporiaye, William L. Redmond, and Christian Capitini
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation., Janis M Taube, Guray Akturk, Michael Angelo, Elizabeth L Engle, Sacha Gnjatic, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Jonathan Juco, Edwin R Parra, Marlon C Rebelatto, David L Rimm, Jaime Rodriguez-Canales, Kurt A Schalper, Edward C Stack, Cláudia S Ferreira, Konstanty Korski, Ana Lako, Scott J Rodig, Emanuel Schenck, Keith E Steele, Michael J Surace, Michael T Tetzlaff, Katharina von Loga, Ignacio I Wistuba, Carlo Bifulco, and Society for Immunotherapy of Cancer (SITC) Pathology Task Force.
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies., Matthew H Taylor, Ajjai S Alva, Timothy Larson, Sebastian Szpakowski, Das Purkaystha, Alpesh Amin, Linda Karpiak, and Sarina A Piha-Paul
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors., Matthew H Taylor, Chung-Han Lee, Vicky Makker, Drew Rasco, Corina E Dutcus, Jane Wu, Daniel E Stepan, Robert C Shumaker, and Robert J Motzer
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors., Matthew H Taylor, Emmett V Schmidt, Corina Dutcus, Elaine M Pinheiro, Yasuhiro Funahashi, Gregory Lubiniecki, and Drew Rasco
Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation., Annabelle Teng, Trang Nguyen, Anton J Bilchik, Victoria O'Connor, and David Y Lee
Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas., Basile Tessier-Cloutier, David F Schaeffer, Julinor Bacani, Celia E Marginean, Steve Kalloger, Martin Köbel, and Cheng-Han Lee
Minimally invasive surgical treatment of intracranial meningiomas in elderly patients (≥ 65 years): outcomes, readmissions, and tumor control., Jai Deep Thakur, Regin Jay Mallari, Alex Corlin, Samantha Yawitz, Weichao Huang, Amy Eisenberg, Walavan Sivakumar, Howard Krauss, Chester Griffiths, Garni Barkhoudarian, and Daniel F Kelly
172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM), Colin Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Joshua Rios, Tarsem Moudgil, Bernard A Fox, Nick Morris, Richard Bryan Bell, and Andrew Weinberg
172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM), Colin Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Joshua Rios, Tarsem Moudgil, Bernard A Fox, Nick Morris, Richard Bryan Bell, and Andrew D Weinberg
Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy., Kyaw Zin Thein, Donald Quick, Thura Win Htut, Lukman Tijani, and Thein Hlaing Oo
Bilateral pulmonary metastases of papillary thyroid carcinoma in a 12-year-old child-A case report and review of the literature., V Thirumala, C O'Souji, and S Thirumala
PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab., Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Eskens, Rachel E Sanborn, Nataliya Volodymyrivna Uboha, Daniel C. Cho, Alexander I. Spira, Igor Bondarenko, Elizabeth Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, Elisabeth De Vries, William Garner, Hendrik-Tobias Arkenau, and Johanna C. Bendell
New Landscape: Physician Compensation., Christian A Thomas, Allison M Hirschorn, Julia E Tomkins, Walter E Birch, Linda D Bosserman, Debra A Patt, Dhimant R Patel, Michael Diaz, Thomas A Marsland, Mary M Klix, Edward P Balaban, Elizabeth M Blanchard, Gregg E Franklin, Rahul Seth, and Andrew Norden
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma., John Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D Zelenetz, Roch Houot, Sattva S Neelapu, Theodore Logan, Izidore S Lossos, Walter Urba, Gilles Salles, Radhakrishnan Ramchandren, Caron Jacobson, John Godwin, Cecilia Carpio, Deanne Lathers, Yali Liu, Jaclyn Neely, Satyendra Suryawanshi, Yoshinobu Koguchi, and Ronald Levy
Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy., Garth W Tormoen, Tiffany C Blair, Shelly Bambina, Gwen Kramer, Jason Baird, Ramtin Rahmani, John M Holland, Owen J T McCarty, Michael J Baine, Vivek Verma, Nima Nabavizadeh, Michael J Gough, and Marka Crittenden
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma., Sherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, Brenda M Sandmaier, Leona A Holmberg, Stephen D Smith, David G Maloney, Brian G Till, Daniel B Martin, Victor A Chow, Joseph G Rajendran, Darrell R Fisher, Manuela C Matesan, Sally J Lundberg, Damian J Green, John M Pagel, Oliver W Press, and Ajay K Gopal
90 Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma, Sherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, Darrell R Fisher, Leona A Holmberg, Pamela S Becker, Sally J Lundberg, Johnnie J Orozco, Ajay K Gopal, Brian G Till, David G Coffey, Margaret E Nartea, Manuela C Matesan, John M Pagel, Joseph G Rajendran, Oliver W Press, William Bensinger, and Damian J Green
PD-1 and PD-L1 Inhibitors: A Single Center Medication Assistance Program (MAP) Experience, Sarah Tu and Shuntao Cai
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy., Chaitra Ujjani, Anthony Mato, Brian T Hill, John N Allan, Frederick Lansigan, Ryan Jacobs, Alan Skarbnik, Hande Tuncer, John M Pagel, Danielle Brander, Bruce Cheson, Paul Barr, Lindsey E Roeker, Jeffrey Pu, Nirav N Shah, Andre Goy, Stephen J Schuster, Nicole Lamanna, Alison Sehgal, Constantine S Tam, and Mazyar Shadman
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia., Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, Peter H Sayre, Matthew J Wieduwilt, Anjali S Advani, John E Godwin, Martha L Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P Erba, Michael Byrne, Laura C Michaelis, Max S Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick Stiff, Kristen Pettit, Bob Löwenberg, Sarah Church, Erica Katherine Anderson, Jayakumar Vadakekolathu, Marianne T Santaguida, Michael P Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B Walter, Jan Kenneth Davidson-Moncada, Sergio Rutella, and John F DiPersio
Prophylactic Ruxolitinib for Cytokine Release Syndrome in Relapse/Refractory AML Patients Treated with Flotetuzumab., Geoffrey L. Uy, Michael P. Rettig, Stephanie Christ, Ibrahim Aldoss, Michael T. Byrne, Harry P. Erba, Martha L. Arellano, Matthew C. Foster, John E Godwin, Farhad Ravandi, Peter H. Sayre, Anjali S. Advani, Matthew J. Wieduwilt, Ashkan Emadi, Laura C. Michaelis, Patrick J. Stiff, Martin Wermke, Norbert Vey, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Fabio Ciceri, Matteo Giovanni Carrabba, Antonio Curti, Geert Huls, Max S. Topp, Mojca Jongen-Lavrencic, John Muth, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, Jian Zhao, Kathy Tran, Patrick Kaminker, Priyanka Patel, Ouiam Bakkacha, Kenneth Jacobs, Maya Kostova, Jennifer Seiler, Bob Lowenberg, Sergio Rutella, Roland B. Walter, Ezio Bonvini, Jan K. Davidson-Moncada, and John F. DiPersio
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML., Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E Church, Tressa Hood, Anbarasu Lourdusamy, Michael P Rettig, Ibrahim Aldoss, Anjali S Advani, John E Godwin, Matthew J Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J M Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F DiPersio, Jan K Davidson-Moncada, and Sergio Rutella
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML., Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E Church, Tressa Hood, Anbarasu Lourdusamy, Michael P Rettig, Ibrahim Aldoss, Anjali S Advani, John E Godwin, Matthew J Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J M Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F DiPersio, Jan K Davidson-Moncada, and Sergio Rutella
Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia, Jayakumar Vadakekolathu, Tung On Yau, Sarah E. Church, Michael P. Rettig, Ibarhim Aldoss, Geoffrey L. Uy, Norbert Vey, Ashkan Emadi, Peter H. Sayre, Roland B. Walter, Matthew C. Foster, Martha L. Arellano, John E Godwin, Matthew J. Wieduwilt, Michael T. Byrne, Laura C. Michaelis, Patrick J. Stiff, Matteo Giovanni Carrabba, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Anjali S. Advani, Martin Wermke, Harry P. Erba, Fabio Ciceri, Geert Huls, Mojca Jongen-Lavrencic, Farhad Ravandi, Antonio Curti, Max S. Topp, John Muth, Patrick Kaminker, Bob Lowenberg, Ivana Gojo, Leo Luznik, John F. DiPersio, Jan K. Davidson-Moncada, and Sergio Rutella
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial., Jayant S Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik L Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman R Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis R Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, David J Joseph, and Jeffrey S Tobias
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer., Jayant S Vaidya, Max Bulsara, Christobel Saunders, Henrik Flyger, Jeffrey S Tobias, Tammy Corica, Samuele Massarut, Frederik Wenz, Steffi Pigorsch, Michael Alvarado, Michael Douek, Wolfgang Eiermann, Chris Brew-Graves, Norman Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Steinar Lundgren, Dennis R Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, Michael Baum, and David Joseph
The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections., Eric Vallieres
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study., Claire F Verschraegen, Guy Jerusalem, Edward F McClay, Nicholas Iannotti, Charles H Redfern, Jaafar Bennouna, Franklin L Chen, Karen Kelly, Janice Mehnert, John C Morris, Matthew H Taylor, David Spigel, Ding Wang, Hans Juergen Grote, Dongli Zhou, Neru Munshi, Marcis Bajars, and James L Gulley
Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival., Chi T Viet, Eric J Dierks, Allen C Cheng, Ashish Patel, Shu-Ching Chang, Marcus Couey, Amber L Watters, Thien Hoang, Hong D Xiao, Marka R Crittenden, Rom Leidner, Steven K Seung, Kristina H Young, and Richard Bryan Bell
Erratum: Viswanathan, A., et al. Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation)., Anisha Viswanathan, Aliyu Musa, Akshaya Murugesan, João R Vale, Carlos A M Afonso, Saravanan Konda Mani, Olli Yli-Harja, Nuno R Candeias, and Meenakshisundaram Kandhavelu
Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC, S Viteri, J Mazieres, R Veillon, E Felip, X Le, MC Garassino, Thomas Stanton, M Morise, J Lee, S Matsumoto, F De Marinis, T Wehler, A Clark, M Friese-Hamim, C Stroh, R Bruns, G Otto, and PK Paik
Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC, S Viteri, J Mazieres, R Veillon, E Felip, X Le, MC Garassino, Thomas Stanton, M Morise, J Lee, S Matsumoto, F De Marinis, T Wehler, A Clark, M Friese-Hamim, C Stroh, R Bruns, G Otto, and PK Paik
Breaking Down the Blood Brain Barrier., Naveed Wagle and Santosh Kesari
Characterization of molecular pathways for targeting therapy in glioblastoma., Naveed Wagle, Minhdan Nguyen, Jose Carrillo, Judy D Truong, Lucia Dobrawa, and Santosh Kesari
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8, Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa Kasiewicz, Daniel Rose, Michael J McNamara, Ian F Hilgart-Martiszus, and William L. Redmond
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma., Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A McSweeney, David B Miklos, John M Pagel, Marie-Jose Kersten, Noel Milpied, Henry Fung, Max S Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M Rossi, Rajul K Jain, Arati V Rao, and Patrick M Reagan
Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors., Xiaowen Wang, Matias A Bustos, Xiaoqing Zhang, Romela Irene Ramos, Cong Tan, Yuuki Iida, Shu-Ching Chang, Matthew P Salomon, Kevin Tran, Rebecca Gentry, Yelena Kravtsova-Ivantsiv, Daniel F Kelly, Gordon B Mills, Aaron Ciechanover, Ying Mao, and Dave S B Hoon
Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression., Ying-Yi Wang, Na Zhou, Hong-Sheng Liu, Xiao-Lei Gong, Rui Zhu, Xiao-Yuan Li, Zhao Sun, Xu-Hong Zong, Ning-Ning Li, Chang-Ting Meng, Chun-Mei Bai, and Tai-Sheng Li
Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls., Yuzhuo Wang, Olga Y Gorlova, Ivan P Gorlov, Meng Zhu, Juncheng Dai, Demetrius Albanes, Stephen Lam, Adonina Tardon, Chu Chen, Gary E Goodman, Stig E Bojesen, Maria Teresa Landi, Mattias Johansson, Angela Risch, Heunz-Erich Wichmann, Heike Bickeboller, David C Christiani, Gad Rennert, Susanne M Arnold, Paul Brennan, John K Field, Sanjay Shete, Loïc Le Marchand, Olle Melander, Hans Brunnstrom, Geoffrey Liu, Rayjean J Hung, Angeline S Andrew, Lambertus A Kiemeney, Shanbeh Zienolddiny, Kjell Grankvist, Mikael Johansson, Neil E Caporaso, Penella J Woll, Philip Lazarus, Matthew B Schabath, Melinda C Aldrich, Victoria L Stevens, Hongxia Ma, Guangfu Jin, Zhibin Hu, Christopher I Amos, and Hongbing Shen
Single-Cell Sequencing-Enabled Hexokinase 2 Assay for Noninvasive Bladder Cancer Diagnosis and Screening by Detecting Rare Malignant Cells in Urine., Zhuo Wang, Jie Chen, Liu Yang, Mingzhe Cao, Yanlan Yu, Rulin Zhang, Heng Quan, Qi Jiang, Yingqi Hua, Wei Wei, Peihua Lu, Jun Wu, and Qihui Shi
Updates to the ASCO Patient-Centered Oncology Payment Model., Jeffery C Ward, Brian R Bourbeau, Alexander L Chin, Ray D Page, Stephen S Grubbs, Deborah Y Kamin, Sybil R Green, and Mary Rappaport
Agonist Abs to TNF Receptor Family Members, Andrew D Weinberg
Can OX40 Agonists Increase the Potency of COVID-19 Vaccines?, Andrew D Weinberg
Identifying Tumor-Reactive CD8 TIL in Patients with Solid Malignancies: Clinical Implications, Andrew D Weinberg
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy., Jared M Weiss, Nathan Pennell, Allison M Deal, Daniel Morgensztern, Daniel S Bradford, Jeffrey Crane, Howard J. West, Carrie Lee, Chad Pecot, James P Stevenson, William Irvin, Mark Socinski, Tom Stinchcombe, Liza C Villaruz, and Hyman B Muss
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction., Daniel K Wells, Marit M van Buuren, Kristen K Dang, Vanessa M Hubbard-Lucey, Kathleen C F Sheehan, Katie M Campbell, Andrew Lamb, Jeffrey P Ward, John Sidney, Ana B Blazquez, Andrew J Rech, Jesse M Zaretsky, Begonya Comin-Anduix, Alphonsus H C Ng, William Chour, Thomas V Yu, Hira Rizvi, Jia M Chen, Patrice Manning, Gabriela M Steiner, Xengie C Doan, Taha Merghoub, Justin Guinney, Adam Kolom, Cheryl Selinsky, Antoni Ribas, Matthew D Hellmann, Nir Hacohen, Alessandro Sette, James R Heath, Nina Bhardwaj, Fred Ramsdell, Robert D Schreiber, Ton N Schumacher, Pia Kvistborg, and Nadine A Defranoux
Somatic mismatch repair testing in evaluation of Lynch syndrome: The gap between preferred and current practices., Danielle Williams, Eduardo Vilar, S Shakrukh Hashmi, Meagan Choates, Sarah Noblin, and Maureen Mork
Electronic Medical Record Inaccuracies: Multicenter Analysis of Challenges with Modified Lung Cancer Screening Criteria., Candice Wilshire, Carson C Fuller, Christopher R Gilbert, John R Handy, Kimberly E Costas, Brian Louie, Ralph W Aye, Alexander S Farivar, Eric Vallières, and Jed A Gorden
Not following the rules in guideline care for lung cancer diagnosis and staging has negative impact., Candice Wilshire, Joshua R Rayburn, Shu-Ching Chang, Christopher R Gilbert, Brian Louie, Ralph W Aye, Alexander S Farivar, Adam J Bograd, Eric Vallières, and Jed A Gorden
Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial., Gregory T Wolf, Siyu Liu, Emily Bellile, Maureen Sartor, Laura Rozek, Dafydd Thomas, Ariane Nguyen, Katie Zarins, Jonathan B McHugh, INSPIRE Trial Clinical Investigators, and R Bryan Bell
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma., Juliet E Wolford, Jiaru Bai, Kathleen N Moore, Rebecca Kristeleit, Bradley J Monk, and Krishnansu S Tewari
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View., Joao B Xavier, Vincent B Young, Joseph Skufca, Fiona Ginty, Traci Testerman, Alexander T Pearson, Paul Macklin, Amir Mitchell, Ilya Shmulevich, Lei Xie, J Gregory Caporaso, Keith A Crandall, Nicole L Simone, Filipa Godoy-Vitorino, Timothy J Griffin, Katrine L Whiteson, Heather H Gustafson, Daniel J Slade, Thomas M Schmidt, Marina R S Walther-Antonio, Tal Korem, Bobbie-Jo M Webb-Robertson, Mark P Styczynski, W Evan Johnson, Christian Jobin, Jason M Ridlon, Andrew Y Koh, Michael Yu, Libusha Kelly, and Jennifer A Wargo
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy., Ke Xu, Dongkyoo Park, Andrew T Magis, Jun Zhang, Wei Zhou, Gabriel L Sica, Suresh S Ramalingam, Walter J Curran, and Xingming Deng
